Can dupilumab heal the skin barrier in eczema patients?
NCT ID NCT04447417
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested whether dupilumab, an injected drug for eczema, improves skin barrier function in 52 people with moderate to severe atopic dermatitis. Researchers measured water loss from the skin after tape stripping to assess barrier repair over 16 weeks. The goal was to see if the drug helps restore the skin's protective layer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dupilumab (injection)
What this could lead to
If successful, this could show that dupilumab helps repair the skin barrier in eczema patients, pointing toward better long-term disease control.
What could go wrong
This is a small, completed phase 4 study with no placebo group, so results may not apply to everyone. It focuses on skin measurements, not long-term symptom relief.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number 1240001
Montreal, H2X 2V1, Canada
-
Investigational Site Number 8400001
Denver, Colorado, 80206, United States